Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”

In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comment addresses Gomez et. al.’s comments with additional inform...

Full description

Bibliographic Details
Main Authors: Matt Wasserman, Maria Gabriela Palacios, Ana Gabriela Grajales, Michele Wilson, Cheryl McDade, Raymond Farkouh
Format: Article
Language:English
Published: Taylor & Francis Group 2019-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
economic evaluation
pneumococcal conjugate vaccine
cost-effectiveness
Online Access:http://dx.doi.org/10.1080/21645515.2018.1558691

Internet

http://dx.doi.org/10.1080/21645515.2018.1558691

Similar Items